Rani Therapeutics (RANI) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rani Therapeutics (RANI) has outperformed vTv Therapeutics (VTVT) over the past year, gaining 61.6% versus a gain of 36.0%. Over five years, VTVT leads with a -48.8% price change compared with -96.0% for RANI. vTv Therapeutics is the larger company by market cap ($118.9 million vs $111.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | VTVT |
|---|---|---|
| Share price | $0.792 | $30.08 |
| Market cap | $111.29M | $118.93M |
| 1-day change | -2.48% | -3.00% |
| YTD return | -41.33% | -24.78% |
| 1-year return | +61.63% | +35.99% |
| 5-year return | -95.98% | -48.84% |
| EPS (TTM) | $-0.15 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.87 | $44.00 |
| 52-week low | $0.445 | $19.50 |
| Distance from 52-week high | -79.53% | -31.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +809.09% | +81.88% |
| Average volume | 743.68K | 68.13K |
| Shares outstanding | 115.42M | 3.95M |
| Employees | 69 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed VTVT by 25.6 percentage points over the past year.
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Healthcare · Biotechnology · 69 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Healthcare · Biotechnology · 26 employees
RANI vs VTVT FAQ
Which is bigger, Rani Therapeutics or vTv Therapeutics?
vTv Therapeutics (VTVT) is larger, with a market capitalization of $118.93M compared with $111.29M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, RANI or VTVT?
RANI returned +61.63% over the past 12 months, compared with +35.99% for VTVT (price return, excluding dividends). Past performance does not predict future results.
Are Rani Therapeutics and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.